The MVRU team and its partners have been a pioneer in discovering and testing new candidates for malaria transmission blocking vaccines (TBVs). These vaccines aim to interrupt transmission of malaria parasites from an infected individual to mosquitoes. Utilizing laboratory reared An. dirus, a Southeast Asian vector of malaria, and malaria infected blood from volunteers, we have been evaluating TBV candidates since 1998 and participated in a clinical Phase I study for the most advanced candidate Pvs25. Together with Mahidol Oxford Research Unit (MORU), we are in the process of initiating the first Controlled Human Malaria Infection study for Plasmodium vivax in a malaria endemic country.
Our works have contributed to down selection of key candidates for P. vivax malaria TBV. Using mosquito membrane feeding assays (MFA), we have shown that several candidates (Pvs25, Pvs28, Pvs45/58, Pvs230, AnAPN1) can significantly reduce malaria infection of mosquito. In some cases, man-to-mosquito transmission of the parasite can be blocked completely. Our works have provided key vaccine efficacy data essential for advancing vaccine candidates to clinical trials.
Publications:
- The fibrinogen-like domain of FREP1 protein is a broad-spectrum malaria transmission-blocking vaccine antigen. J Biol Chem.. 2017-07-01
- Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission. PLoS Negl Trop Dis.. 2016-12-08
- Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization. Vaccine. 2015-04-01
- Differential roles of an Anopheline midgut GPI-anchored protein in mediating Plasmodium falciparum and Plasmodium vivax ookinete invasion. Infect Genet Evol.. 2014-12-20
- Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria. Infect Immun.. 2014-02-01
- Tricomponent complex loaded with a mosquito-stage antigen of the malaria parasite induces potent transmission-blocking immunity. Clin Vaccine Immunol.. 2014-04-01
- Natural infection of Plasmodium falciparum induces inhibitory antibodies against gametocyte development in human hosts. Jpn J Infect Dis.. 2012-01-20
- Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate. Vaccine. 2012-02-20
- Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development. Infect Immun.. 2011-10-01
- N-terminal prodomain of Pfs230 synthesized using a cell-free system is sufficient to induce complement-dependent malaria transmission-blocking activity. Clin Vaccine Immunol.. 2011-08-01
- Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine. Vaccine. 2011-03-20
- Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine. 2010-08-16
- Plasmodium vivax ookinete surface protein Pvs25 linked to cholera toxin B subunit induces potent transmission-blocking immunity by intranasal as well as subcutaneous immunization. Infect Immun.. 2010-09-01
- Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria. Vaccine. 2005-05-01
- Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect Immun.. 2005-11-01
- Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy. Vaccine. 2004-08-01
- Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates. Am J Trop Med Hyg.. 2003-11-03
- Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine. 2003-07-01
- Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes. Infect Immun.. 2006-12-01
Key Information
Key MVRU Researchers:
Gallery
